Migibio
Blog

Creatinine vs SDMA: Which Catches Kidney Disease First?

· By Dr. Tang

TL;DR — The classic teaching is that SDMA catches kidney disease earlier: it rises at about 40% GFR loss (as early as 25%), while creatinine stays normal until about 75% of function is gone. That is true — but the story the marketing skips is that one independent head-to-head study found SDMA and creatinine had the same overall diagnostic accuracy (AUC), with both hitting about 90% sensitivity at their cut-offs. The real value of SDMA is not “more accurate” — it is muscle-mass independent and earlier in acute injury. The correct answer to “which is better?” is: use both, and read the trend, because creatinine alone hides disease in thin patients and SDMA alone can be over-read in a dehydrated one.

In Plain Terms

Your kidneys filter waste like a warehouse staff that is massively over-staffed. You can lose half the workers and the warehouse still runs fine. Creatinine is the metric that only moves when the staffing gets really thin — around three-quarters gone. SDMA is the metric that starts to wobble when you’ve lost roughly two-fifths.

So SDMA is the earlier alarm. The nuance that matters is that “earlier” and “more accurate” are not the same thing — and that distinction is where most of the confusion (and the marketing) lives.

The Numbers Behind the Claim

MarkerWhen it risesMuscle-mass effectCorrelation with GFR
Creatinine~75% GFR lossStrong (falls in thin/cachectic patients)Indirect
SDMA~40% average, as early as 25%MinimalR² ≈ 0.82 cat, 0.85 dog

A useful third data point: urine concentrating ability starts to decline at around 66% GFR loss — later than SDMA but earlier than creatinine. This is why an early-CKD patient can have a high SDMA, a normal creatinine, and still-concentrated urine, all at once.

The Part the Marketing Skips

SDMA is marketed as the “more sensitive” early marker, and for early detection that is directionally right. But an independent study (comparing SDMA, cystatin C and creatinine against measured GFR in stable dogs) reached a conclusion worth knowing:

SDMA and creatinine had the same overall diagnostic performance (AUC). At their respective cut-offs (creatinine 1.3 mg/dL; SDMA 14 µg/dL), both were ~90% sensitive for detecting reduced GFR, with specificity ~90% for creatinine and ~87% for SDMA.

What this means in practice: SDMA’s edge is not that it is a fundamentally more accurate test. Its real, defensible advantages are narrower and more specific:

  1. It is muscle-mass independent. A thin elderly cat or a cachectic dog can have a falsely normal creatinine that masks genuine kidney disease. SDMA does not have that blind spot.
  2. It rises earlier in acute kidney injury. In a hospitalized patient being serially monitored after a toxin (lily ingestion, NSAID toxicity), SDMA flags the fall in GFR days before creatinine moves.
  3. It is a cleaner trend signal. SDMA varies less with diet and hydration than creatinine, so a climbing SDMA series is a more trustworthy slope.

The Creatinine Blind Spot That Costs Lives

Here is the failure mode every clinician has seen: an old, skinny cat with early CKD whose creatinine reads “normal” because the cat has lost so much muscle that the creatinine pool itself is smaller. The kidneys are failing, but the marker that should catch it is being suppressed by sarcopenia.

This is exactly the patient where SDMA earns its keep — a normal creatinine with a persistently elevated SDMA (above 14 µg/dL, and especially a stable 15–17 µg/dL) is a red flag for early CKD that creatinine would have missed for months or years.

The Pair Beats Either Alone

The highest-sensitivity approach for an at-risk patient is to run both and read them together:

  • Creatinine normal + SDMA normal → kidneys likely fine; recheck at the next wellness visit.
  • Creatinine normal + SDMA elevated (15–17 µg/dL) → early CKD likely; confirm with a repeat in 4–6 months and add a urine protein:creatinine ratio (UPC).
  • Both elevated → stage with the IRIS system and start management.
  • Creatinine elevated + SDMA normal → suspicious for a pre-renal or muscle-mass artifact; investigate before diagnosing CKD.

The pair also anchors the IRIS staging system, which uses both creatinine and SDMA — so running both gives you the data you need to stage without a second draw.

When SDMA Alone Can Mislead

SDMA is not infallible. A single elevated value can reflect dehydration, pre-renal factors, or lab variation, so the rule is the same as for creatinine: persistence, not one reading, is what matters. A transiently high SDMA on a dehydrated patient is a reason to rehydrate and re-test, not to declare CKD. This is why the IRIS guidance specifies persistent elevation above the reference interval (with values of 15–17 µg/dL placed in stage 1) as the diagnostic criterion.

How the Test Runs

  1. Draw blood for a chemistry panel (creatinine) plus SDMA.
  2. Run creatinine on the standard panel and SDMA on a quantitative immunofluorescence analyzer.
  3. Confirm any elevation with a repeat in 4–6 weeks (sooner if clinical signs or urinary abnormalities are present).
  4. Stage a confirmed CKD using both markers on the IRIS scale, and add a UPC for proteinuria substaging.

Related products: SDMA Chronic Kidney Disease Kit · FIA680 Analyzer · FIA880 Analyzer

FAQ

Does SDMA detect kidney disease earlier than creatinine?

Yes on timing, not on accuracy — SDMA rises at ~40% GFR loss (as early as 25%) vs creatinine at ~75%. But one independent study found the same AUC for both (~90% sensitivity). “Earlier” is not the same as “more accurate.”

Why is creatinine a late marker?

Because of ~75% nephron reserve — creatinine stays normal until about 75% of function is gone, and it is suppressed by low muscle mass, so a thin patient can read falsely normal.

What is SDMA’s real advantage?

Muscle-mass independence — SDMA (R² ≈ 0.82 cat / 0.85 dog vs GFR) does not fall just because a patient is thin, and it rises earlier in acute kidney injury, making it ideal for serial toxin monitoring.

Should I use SDMA or creatinine?

Both — creatinine is cheap and anchors IRIS staging (stage 1 <1.4/1.6 mg/dL); SDMA adds the muscle-mass-independent early signal, rising at ~40% GFR loss. The pair plus their trend is the highest-sensitivity approach.

What are the reference ranges?

SDMA upper limit 14 µg/dL (both species); a persistent 15–17 µg/dL = IRIS stage 1. Creatinine stage 1 is <1.4 mg/dL (dog) and <1.6 mg/dL (cat).

Can SDMA be falsely elevated?

Yes — dehydration and pre-renal factors can transiently raise it. Persistence above 14 µg/dL, not one reading, supports a CKD diagnosis.

Key Takeaways

  1. The timing gap is real — SDMA rises at ~40% GFR loss (as early as 25%); creatinine waits until ~75%. That is a genuine head start in early and acute disease.
  2. But “earlier” ≠ “more accurate” — an independent head-to-head found SDMA and creatinine had the same AUC (~90% sensitivity). SDMA’s defensible edge is narrower than the marketing implies.
  3. The real win is muscle-mass independence — a thin elderly cat with a “normal” creatinine and an SDMA above 14 µg/dL (persistent 15–17) is early CKD that creatinine would have hidden for months.
  4. Run the pair — creatinine anchors IRIS staging (stage 1 <1.4/1.6 mg/dL), SDMA catches the early and the thin. Together they cover both blind spots.
  5. Persistence beats a single reading — a transiently high SDMA in a dehydrated patient is a re-test, not a diagnosis. Only a persistent elevation above 14 µg/dL supports CKD.

References

This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected kidney disease should be evaluated by a veterinarian. Reference ranges are platform-dependent; always use the intervals validated for your specific analyzer. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.

Continue exploring